ReviewClinical and translational science2019
Emerging Role of Organ-on-a-Chip Technologies in Quantitative Clinical Pharmacology Evaluation.
Review in Clinical and translational science, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 45 citations in OpenAlex.
- PK-Informed Microphysiological Systems: From Dynamic Dosing to Quantitative In Vitro-In Vivo Translation.Pharmaceutics · 2026Review
- Organs-on-Chips in Drug Development: Engineering Foundations, Artificial Intelligence, and Clinical Translation.Biosensors · 2026Review
- The Impact of QSP Modeling on the Design and Optimization of Gene Therapy Approaches.CPT: pharmacometrics & systems pharmacology · 2025Review
- Revolutionizing cancer care: Bioprinting prostate cancer stem cells for targeted treatments.World journal of clinical oncology · 2025Review
- Organoid, organ-on-a-chip and traditional Chinese medicine.Chinese medicine · 2025Review
- Microphysiological systems as reliable drug discovery and evaluation tools: Evolution from innovation to maturity.Biomicrofluidics · 2023Review
- Organs-on-Chips Platforms Are Everywhere: A Zoom on Biomedical Investigation.Bioengineering (Basel, Switzerland) · 2022Review
- Kidney microphysiological models for nephrotoxicity assessment.Current opinion in toxicology · 2022Article
- Modeling Neurodegenerative Diseases UsingFrontiers in bioengineering and biotechnology · 2022Review
- 3D cell culture models: Drug pharmacokinetics, safety assessment, and regulatory consideration.Clinical and translational science · 2021Review
- Lab-on-a-Chip Platforms as Tools for Drug Screening in Neuropathologies Associated with Blood-Brain Barrier Alterations.Biomolecules · 2021Review
- Measuring barrier function in organ-on-chips with cleanroom-free integration of multiplexable electrodes.Lab on a chip · 2021Article
- Characterizing the reproducibility in using a liver microphysiological system for assaying drug toxicity, metabolism, and accumulation.Clinical and translational science · 2021Article
- Mimicking and surpassing the xenograft model with cancer-on-chip technology.EBioMedicine · 2021Review
- Human biomimetic liver microphysiology systems in drug development and precision medicine.Nature reviews. Gastroenterology & hepatology · 2021Review
- Microphysiological systems for the modeling of wound healing and evaluation of pro-healing therapies.Journal of materials chemistry. B · 2020Review
- A Perspective on Expanding Our Understanding of Cancer Treatments by Integrating Approaches from the Biological and Physical Sciences.SLAS discovery : advancing life sciences R & D · 2020Article
- Simulation of nanoparticle transport and adsorption in a microfluidic lung-on-a-chip device.Biomicrofluidics · 2020Article
- Integrating Biophysics in Toxicology.Cells · 2020Review
- Applications of the microphysiology systems database for experimental ADME-Tox and disease models.Lab on a chip · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The recently enacted Prescription Drug User Fee Act (PDUFA) VI includes in its performance goals "enhancing regulatory science and expediting drug development." The key elements in "enhancing regulatory decision tools to support drug development and review" include "advancing model-informed drug development (MIDD)." This paper describes (i) the US Food and Drug Administration (FDA) Office of Clinical Pharmacology's continuing efforts in developing quantitative clinical pharmacology models (disease, drug, and clinical trial models) to advance MIDD, (ii) how emerging novel tools, such as organ-on-a-chip technologies or microphysiological systems, can provide new insights into physiology and disease mechanisms, biomarker identification and evaluation, and elucidation of mechanisms of adverse drug reactions, and (iii) how the single organ or linked organ microphysiological systems can provide critical system parameters for improved physiologically-based pharmacokinetic and pharmacodynamic evaluations. Continuous public-private partnerships are critical to advance this field and in the application of these new technologies in drug development and regulatory review.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.